

# DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

8 February September 2015



**Remember: Clicking the [coloured links](#) will take you to more information!**

Don't forget: DRIVE-AB is on [Twitter](#)! Don't miss a beat - follow us at [@DRIVE\\_AB](#).

It's easier than ever for you to get involved! Just go to our website and click "[Stakeholder Engagement](#)" to find out all you need to know about getting involved with the project!

Or, fill out our [Expression of Interest Form](#) for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this newsletter with other interested stakeholders as well!

## What's New?

### DRIVE-AB is planning its first conference to explore feasible policy solutions to the problems facing antibiotic R&D

The consortium is putting together a **high-level conference** to bring together policy makers, regulatory and public health experts, and economists on **2 June 2016 in Amsterdam** to identify and evaluate reward models that are feasible, practical and can be implemented globally. To read more, [please see our website](#).

### DRIVE-AB WP 2 Publishes Report: Solutions from other industries applicable to the antibiotic field

On January 12, WP2 released a report on their assessment of reward and business models in other industries that promote conservation and that address key challenges that are similar to those faced in the field of antibiotics. [Click here to read the report](#).

### DRIVE-AB participants attend high-level meetings

DRIVE-AB participants have attended two high-level meetings so far this year to actively participate in and provide critical input to the shaping of the future antimicrobial resistance agenda.

- **"Brainstorming options for a global development and stewardship framework for antimicrobial medicines"** - Hosted by the WHO Department of Essential Medicines and Health Products in collaboration with the AMR Secretariat on 1 February at the World Health

- **“Workshop: Transatlantic collaboration on clinical trials related to antimicrobial resistance”** - IMI meeting held on 21-22 January in Stockholm, Sweden.

## Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

On January 21 the **Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance** was launched at an event at the World Economic Forum in Davos, Switzerland. The Declaration was agreed and signed by 85 companies and nine industry associations from across the global pharmaceutical, biotechnology and diagnostics industries in 18 different countries. [Click here to read the Declaration.](#)

## Prof Kevin Outterson wins Leaders Award 2015



The **Alliance for the Prudent Use of Antibiotics** (APUA) has named Kevin Outterson, DRIVE-AB Work Package 2 participant and professor at the Boston

University School of Law and Boston University School of Public Health, as the recipient of its **2015 Leadership Award** for his efforts to contain antibiotic resistance.

## Prof Otto Cars wins prestigious research prize

Professor Otto Cars, member of DRIVE-AB and founder of **ReAct**, received the **Olof Rudbeck Prize** at Uppsala University, Sweden. This prize goes to "one scientist who made outstanding contributions to basic research with great clinical significance".



UPPSALA  
UNIVERSITET

## DRIVE-AB Supports World Health Organization Survey on Antimicrobial Resistance



The **WHO** invites professionals working with AMR to participate in a short survey about the World Health Organization's activities for prevention and containment of antimicrobial resistance. The anonymous survey will be used to support the WHO in implementing its Global Action Plan.

For more information, [click here](#). [Please click here to go directly to the survey.](#)

## Our upcoming events with presentations by DRIVE-AB members

**BSAC Roundtable Series on Antimicrobial Resistance - London, UK, 10 February 2016**

DRIVE-AB will be presenting at the British Society for Antimicrobial Chemotherapy

(BSAC) Roundtable Series in February in London, UK. The series will examine the economic,



The British Society for  
Antimicrobial Chemotherapy

societal and human impact of antimicrobial resistance and look at the vital role of education in minimising this. For more information about this meeting, [please see the meeting website](#).



### **International Congress on Infectious Diseases - Hyderabad, India, 2-5 March 2016**

DRIVE-AB will be involved in a session at the the International Congress on Infectious Diseases in Hyderabad, India, in March. The Congress has a focus on the global burden of infectious diseases, with particular attention on some of the major challenges of this region including AIDS, malaria, tuberculosis, pneumonia, and enteric infections. For more information about this meeting, please see the [meeting website](#).

### **Gordon Research Conference on New Antibacterial Discovery and Development - Lucca, Italy, 13-18 March 2016**



DRIVE-AB participants Prof Laura Piddock and Dr Ursula Theuretzbacher have been invited to speak at this year's Gordon Research Conference. The conference will bring together experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. For more information about this meeting, please see the [meeting website](#).

## **Project updates by work package**

### **Work Package 1**

#### **WP1A: Responsible use of antibiotics, new and old**

The team has finished analysing the results of their stakeholder survey on metrics and quality indicators of responsible use and is in the process of completing surveys on responsible use definitions as well as preparing stakeholder interviews on barriers to responsible use, which will be held throughout the spring and summer this year. Work package 1A will also be holding a Train-the-Trainer event in parallel to ECCMID (European Congress on Clinical Microbiology and Infectious Diseases) in April 2016; the event will aim to inform high-level experts from across the EU on how to facilitate successful antimicrobial stewardship training programs in their own countries. Five WP1A abstracts covering the systematic reviews of metrics and quality indicators of responsible antibiotic use have been submitted to the European Congress on Clinical Microbiology and Infectious Diseases.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [WP1A's stakeholder engagement page](#).

#### **WP1B: Setting, communicating and revising public health priorities**

The team has begun data mining of international antimicrobial resistance surveillance systems and are completing a literature review on the earliest reports and initial spread of multidrug-resistant organisms (MDROs) and modelling this spread both between institutions and between regions. A model of MDRO spread within hospitals has been completed and will be followed by a published article in the near future. The group will also be beginning work on systematic reviews of outbreaks and the clinical impact of antimicrobial resistance over the next few months.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [WP1B's stakeholder engagement page](#).

#### **WP1C: Antibiotic Evaluation**

This work package has worked hard to develop case studies with Work package 2. Over the next few months, the team will begin work on an option value model for antibiotics which will examine the example of a pandemic flu with resistant secondary bacterial infections as well as continue their

ongoing discussions with EFPIA partners and health technology assessment (HTA) stakeholders on the challenges of HTA for antibiotics.

For more detailed information on the group's progress and to find out how you can get involved, please see [WP1C's stakeholder engagement page](#).

## Work Package 2

### WP2: Creation and testing of new economic models

The group has completed their report titled, "Solutions from other industries applicable to the antibiotic field". This year, the team will continue their work on selecting and refining new reward models and laying the groundwork for the eventual implementation plan for DRIVE-AB reward model recommendations. They will also be presenting at the [International Congress on Infectious Diseases](#) in Hyderabad in March. Within the next two months, the team hopes to have published two articles: an article about alternative technologies and an article on the Norwegian case on the HTA, regulatory and reimbursement processes.

For more detailed information on the group's progress and to find out how you can get involved, please see [WP2's stakeholder engagement page](#).

## Work Package 3

### WP3A: Project management and governance

The project management office has completed and submitted the Year 1 report and deliverables to the [Innovative Medicines Initiative](#). Along with ongoing project management activities, the team has been supporting WP3B in the planning of the [DRIVE-AB conference](#) which will be coming up in June and will be held in Amsterdam.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

### WP3B: Stakeholder platform and external communication

The team is currently busy planning the [DRIVE-AB conference for policy-makers, which be held in Amsterdam in June 2016](#). In addition to this, they have been continuing other communications activities such as monitoring and updating the website, the Twitter account, the newsletters, planning of other upcoming meetings, and managing potential and novel stakeholders. stakeholder engagement.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

## Other news

Don't forget about the two-sided information card offering a full, summarized [overview of the DRIVE-AB project](#). These information cards are available for download on the [DRIVE-AB website](#), along with other resources.

**Please share these information cards with any colleagues or friends that may be interested in the project the more stakeholders we have, the more robust and relevant our outputs will be!**

**Should you wish to receive more detailed information, nominate another stakeholder or update us on your activities relevant to the project, please contact [Victoria Wells](#), DRIVE-AB Communications Officer.**

# DRIVE AB

RE-INVESTMENT  
IN R&D AND RESPONSIBLE  
ANTIBIOTIC USE

www.drive-ab.eu

#DRIVE\_AB

## Driving reinvestment in R&D for antibiotics and advocating their responsible use

DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and is composed of 16 public and 7 private partners from 12 countries.

### What is the problem?

Antibiotic resistance is a global public health threat that is getting worse every year. It is estimated that antibacterial drug resistance costs the EU at least EUR 1.5 billion and 25 000 lives each year. The development of new drugs to treat resistant infections is falling behind; new economic models that offer incentives for the discovery and development of new antibiotics and reconcile these with responsible antibiotic use and access are long overdue.



### What we plan to do

- Define standards and metrics for **responsible antibiotic use**
- Estimate the current and future **impact of antibiotic resistance** on societies in order to determine future public health needs
- Quantify the value of **new antibiotics**
- Create, test and validate **new economic models** to incentivise the discovery and development of new antibiotics
- Recommend to governments and policy-makers **new economic models** that stimulate innovation, responsible use and global access of novel antibiotics to meet public health needs



[Edit your subscription](#) | [Unsubscribe](#)